Scholarlink

Purpose <p>Degeneration at the common extensor origin leads to lateral elbow pain and reduced quality of life. We conducted a double-blind, randomized, placebo-controlled trial involving 71 patients treated with leukocyte-poor PRP (LP-PRP), leukocyte-rich PRP (LR-PRP), or saline.</p> Methods <p>PRP content was analyzed using flow cytometry, confocal microscopy, and holotomography. Clinical outcomes (Visual Analogue Scale, Oxford Elbow Score) were assessed at baseline and at three, six, 12, 24, and 55&#xa0;weeks.</p> Results <p>LR-PRP contained 3.8 × more leukocytes and 2.7 × fewer platelets than LP-PRP. Imaging revealed distinct platelet morphology and activation patterns between PRP types. The LP-PRP group showed significantly greater pain reduction at six&#xa0;weeks and improved elbow function from three to six&#xa0;weeks onward.</p> Conclusion <p>LP-PRP produced superior and longer-lasting clinical outcomes compared to LR-PRP and saline.</p> ClinicalTrials.gov <p>NCT06854666 (retrospectively registered on 2025–01-13).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Molecular background behind lateral elbow pain reduction with Leukocyte-Rich and Leukocyte-Poor Platelet-Rich Plasma—randomized control trial and single-cell platelet analysis

  • 期刊论文

  • 发表日期：

    2026年1月24日

查看全文
  • Joanna Wałecka,
  • Paweł Bąkowski,
  • Marta Jokiel,
  • Rafał Trąbka,
  • Monika Chaszczewska-Markowska,
  • Daniel Ghete,
  • Dorota Gurda-Woźna,
  • Agnieszka Fedoruk-Wyszomirska,
  • Przemyslaw Lubiatowski,
  • Eliza Wyszko,
  • Agata Tyczewska,
  • Kamilla Bąkowska-Żywicka

摘要

Purpose

Degeneration at the common extensor origin leads to lateral elbow pain and reduced quality of life. We conducted a double-blind, randomized, placebo-controlled trial involving 71 patients treated with leukocyte-poor PRP (LP-PRP), leukocyte-rich PRP (LR-PRP), or saline.

Methods

PRP content was analyzed using flow cytometry, confocal microscopy, and holotomography. Clinical outcomes (Visual Analogue Scale, Oxford Elbow Score) were assessed at baseline and at three, six, 12, 24, and 55 weeks.

Results

LR-PRP contained 3.8 × more leukocytes and 2.7 × fewer platelets than LP-PRP. Imaging revealed distinct platelet morphology and activation patterns between PRP types. The LP-PRP group showed significantly greater pain reduction at six weeks and improved elbow function from three to six weeks onward.

Conclusion

LP-PRP produced superior and longer-lasting clinical outcomes compared to LR-PRP and saline.

ClinicalTrials.gov

NCT06854666 (retrospectively registered on 2025–01-13).